Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data

Drug Metabolism and Disposition

Volumn 40, Issue 9, 2012, Pages 1771-1777

  Nakamori, Fumihiro ^a,b   Naritomi, Yoichi ^a   Hosoya, Ken Ichi ^b   Moriguchi, Hiroyuki ^a   Tetsuka, Kazuhiro ^a   Furukawa, Takako ^a   Kadono, Keitaro ^a   Yamano, Katsuhiro ^a   Terashita, Shigeyuki ^a   Teramura, Toshio ^a  

^a ASTELLAS PHARMA INC   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BAZEDOXIFENE; DIAZEPAM; DICLOFENAC; ENTACAPONE; ETODOLAC; GEMFIBROZIL; GLUCURONOSYLTRANSFERASE; INDOMETACIN; ISOENZYME; QUERCETIN; RALOXIFENE; TELMISARTAN; TOLCAPONE; TOLFENAMIC ACID;

ARTICLE; CALCULATION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG CONJUGATION; DRUG GLUCURONIDATION; ENZYME SUBSTRATE; FIRST PASS EFFECT; IN VITRO STUDY; IN VIVO STUDY; INSECT CELL; INTESTINE; MICROSOME; PREDICTION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; BIOTRANSFORMATION; CELL MEMBRANE PERMEABILITY; CYTOCHROME P-450 ENZYME SYSTEM; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; INTESTINAL ABSORPTION; INTESTINES; ISOENZYMES; KINETICS; METABOLIC CLEARANCE RATE; MICROSOMES; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY;

EID: 84865196896     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.045476     Document Type: Article

References (38)

1. Chandrasekaran A, Ermer J, McKeand W, Lee H, DeMaio W, Kotake A, Sullivan P, Orczyk G, and Scatina J (2003) Bazedoxifene acetate metabolic disposition in healthy, postmenopausal women (Abstract). Clin Pharmacol Ther 73:47.
2. Chandrasekaran A, McKeand WE, Sullivan P, DeMaio W, Stoltz R, and Scatina J (2009) Metabolic disposition of [14C]bazedoxifene in healthy postmenopausal women. Drug Metab Dispos 37:1219-1225.
3. Cubitt HE, Houston JB, and Galetin A (2009) Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance. Pharm Res 26:1073-1083.
4. Cubitt HE, Houston JB, and Galetin A (2011) Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data. Drug Metab Dispos 39:864-873.
5. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095. (Pubitemid 23211439)
6. Duggan DE, Hogans AF, Kwan KC, and McMahon FG (1972) The metabolism of indomethacin in man. J Pharmacol Exp Ther 181:563-575.
7. Ellingson T, Duddempudi S, Greenberg BD, Hooper D, and Eisenhofer G (1999) Determination of differential activities of soluble and membrane-bound catechol-O-methyltransferase in tissues and erythrocytes. J Chromatogr B Biomed Sci Appl 729:347-353. (Pubitemid 29264142)
8. Ferdinandi ES, Sehgal SN, Demerson CA, Dubuc J, Zilber J, Dvornik D, and Cayen MN (1986) Disposition and biotransformation of 14C-etodolac in man. Xenobiotica 16:153-166.
9. Furukawa T, Nakamori F, Tetsuka K, Naritomi Y, Moriguchi H, Yamano K, Terashita S, and Teramura T (2012) Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data. Drug Metab Pharmacokinet 27:171-180.
10. Graefe EU, Wittig J, Mueller S, Riethling AK, Uehleke B, Drewelow B, Pforte H, Jacobasch G, Derendorf H, and Veit M (2001) Pharmacokinetics and bioavailability of quercetin glycosides in humans. J Clin Pharmacol 41:492-499. (Pubitemid 32381866)
11. Heikkinen H, Saraheimo M, Antila S, Ottoila P, and Pentikäinen PJ (2001) Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. Eur J Clin Pharmacol 56:821-826. (Pubitemid 33788554)
12. Jones C (1997) Clinical pharmacology & biopharmaceutical review for EVISTA™. Submitted to FDA Dec 9; NDA 20-815.
13. Jorga K, Fotteler B, Heizmann P, and Gasser R (1999) Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase. Br J Clin Pharmacol 48:513-520. (Pubitemid 29454231)
14. Jorga KM, Fotteler B, Heizmann P, and Zürcher G (1998) Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy. Eur J Clin Pharmacol 54:443-447. (Pubitemid 28396320)
15. Kadono K, Akabane T, Tabata K, Gato K, Terashita S, and Teramura T (2010) Quantitative prediction of intestinal metabolism in humans from a simplified intestinal availability model and empirical scaling factor. Drug Metab Dispos 38:1230-1237.
16. Kemp DC, Fan PW, and Stevens JC (2002) Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab Dispos 30:694-700. (Pubitemid 34579104)
17. Mizuma T (2009) Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10. Int J Pharm 378:140-141.
18. Nakamori F, Naritomi Y, Furutani M, Takamura F, Miura H, Murai H, Terashita S, and Teramura T (2011) Correlation of intrinsic in vitro and in vivo clearance for drugs metabolized by hepatic UDP-glucuronosyltransferases in rats. Drug Metab Pharmacokinet 26:465-473.
19. Obach RS, Lombardo F, and Waters NJ (2008) Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos 36: 1385-1405. (Pubitemid 351929323)
20. Ohno S and Nakajin S (2009) Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 37:32-40.
21. Okerholm RA, Keeley FJ, Peterson FE, and Glazko AJ (1976) The metabolism of gemfibrozil. Proc R Soc Med 69 (Suppl 2):11-14.
22. Patat A, McKeand W, Baird-Bellaire S, Ermer J, and LeCoz F (2003) Absolute bioavailability of bazedoxifene acetate in healthy postmenopausal women (Abstract). Clin Pharmacol Ther 73:43.
23. Pentikäinen PJ, Neuvonen PJ, and Backman C (1981) Human pharmacokinetics of tolfenamic acid, a new anti-inflammatory agent. Eur J Clin Pharmacol 19:359-365. (Pubitemid 11103882)
24. Pentikäinen PJ, Tokola O, Alhava E, and Penttilä A (1984) Pharmacokinetics of tolfenamic acid: disposition in bile, blood and urine after intravenous administration to man. Eur J Clin Pharmacol 27:349-354.
25. Shen L, Ahmad S, Park S, DeMaio W, Oganesian A, Hultin T, Scatina J, Bungay P, and Chandrasekaran A (2010) In vitro metabolism, permeability, and efflux of bazedoxifene in humans. Drug Metab Dispos 38:1471-1479.
26. Soars MG, Burchell B, and Riley RJ (2002) In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J Pharmacol Exp Ther 301:382-390. (Pubitemid 34250317)
27. Stangier J, Schmid J, Türck D, Switek H, Verhagen A, Peeters PA, van Marle SP, Tamminga WJ, Sollie FA, and Jonkman JH (2000) Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers. J Clin Pharmacol 40:1312-1322.
28. Stierlin H and Faigle JW (1979) Biotransformation of diclofenac sodium (Voltaren) in animals and in man. II. Quantitative determination of the unchanged drug and principal phenolic metabolites, in urine and bile. Xenobiotica 9:611-621. (Pubitemid 10167100)
29. Stierlin H, Faigle JW, Sallmann A, Küng W, Richter WJ, Kriemler HP, Alt KO, and Winkler T (1979) Biotransformation of diclofenac sodium (Voltaren) in animals and in man. I. Isolation and identification of principal metabolites. Xenobiotica 9:601-610. (Pubitemid 10167099)
30. Tachibana T, Kato M, Watanabe T, Mitsui T, and Sugiyama Y (2009) Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein. Xenobiotica 39:430-443.
31. Thummel KE, Shen DP, Isoherran N, and Smith HE (2005) Design and optimization of dosage regimes: pharmacokinetic data, in Goodman & Gilman's the Pharmacological Basis of Therapeutics (Brunton LL, Chabner BA, and Knollmann BC eds) 12th ed, pp 1787-1888, McGraw-Hill, New York.
32. Walgren RA, Walle UK, and Walle T (1998) Transport of quercetin and its glucosides across human intestinal epithelial Caco-2 cells. Biochem Pharmacol 55:1721-1727. (Pubitemid 28223464)
33. Wikberg T, Vuorela A, Ottoila P, and Taskinen J (1993) Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans. Drug Metab Dispos 21:81-92. (Pubitemid 23052226)
34. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, and Ball SE (2004) Drug-drug interactions for UDP- glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201-1208. (Pubitemid 39410902)
35. Willis JV, Kendall MJ, Flinn RM, Thornhill DP, and Welling PG (1979) The pharmacokinetics of diclofenac sodium following intravenous and oral administration. Eur J Clin Pharmacol 16:405-410. (Pubitemid 10173752)
36. Wong H, Tong V, Riggs KW, Rurak DW, Abbott FS, and Kumar S (2007) Kinetics of valproic acid glucuronidation: evidence for in vivo autoactivation. Drug Metab Dispos 35:1380-1386. (Pubitemid 47121779)
37. Yang J, Jamei M, Yeo KR, Tucker GT, and Rostami-Hodjegan A (2007) Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 8:676-684. (Pubitemid 47578116)
38. Yoon IS, Choi MK, Kim JS, Shim CK, Chung SJ, and Kim DD (2011) Pharmacokinetics and first-pass elimination of metoprolol in rats: contribution of intestinal first-pass extraction to low bioavailability of metoprolol. Xenobiotica 41:243-251.